1. Cancer statistics, 2015;Siegel;CA Cancer J. Clin.,2015
2. Attributable causes of esophageal cancer incidence and mortality in China;Wang;PLoS One,2012
3. Global incidence of oesophageal cancer by histological subtype in 2012;Arnold;Gut,2015
4. Oesophageal cancer;Lagergren;Lancet,2017
5. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet;Catenacci;Oncology,2017